Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.

CT Diffusion-weighted Imaging Dynamic Contrast-enhanced MRI Liver Lung MRI Oncology Radiomics Unsupervised Learning

Journal

Radiology. Artificial intelligence
ISSN: 2638-6100
Titre abrégé: Radiol Artif Intell
Pays: United States
ID NLM: 101746556

Informations de publication

Date de publication:
Mar 2024
Historique:
pubmed: 31 1 2024
medline: 31 1 2024
entrez: 31 1 2024
Statut: ppublish

Résumé

Purpose To identify precise three-dimensional radiomics features in CT images that enable computation of stable and biologically meaningful habitats with machine learning for cancer heterogeneity assessment. Materials and Methods This retrospective study included 2436 liver or lung lesions from 605 CT scans (November 2010-December 2021) in 331 patients with cancer (mean age, 64.5 years ± 10.1 [SD]; 185 male patients). Three-dimensional radiomics were computed from original and perturbed (simulated retest) images with different combinations of feature computation kernel radius and bin size. The lower 95% confidence limit (LCL) of the intraclass correlation coefficient (ICC) was used to measure repeatability and reproducibility. Precise features were identified by combining repeatability and reproducibility results (LCL of ICC ≥ 0.50). Habitats were obtained with Gaussian mixture models in original and perturbed data using precise radiomics features and compared with habitats obtained using all features. The Dice similarity coefficient (DSC) was used to assess habitat stability. Biologic correlates of CT habitats were explored in a case study, with a cohort of 13 patients with CT, multiparametric MRI, and tumor biopsies. Results Three-dimensional radiomics showed poor repeatability (LCL of ICC: median [IQR], 0.442 [0.312-0.516]) and poor reproducibility against kernel radius (LCL of ICC: median [IQR], 0.440 [0.33-0.526]) but excellent reproducibility against bin size (LCL of ICC: median [IQR], 0.929 [0.853-0.988]). Twenty-six radiomics features were precise, differing in lung and liver lesions. Habitats obtained with precise features (DSC: median [IQR], 0.601 [0.494-0.712] and 0.651 [0.52-0.784] for lung and liver lesions, respectively) were more stable than those obtained with all features (DSC: median [IQR], 0.532 [0.424-0.637] and 0.587 [0.465-0.703] for lung and liver lesions, respectively;

Identifiants

pubmed: 38294307
doi: 10.1148/ryai.230118
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e230118

Commentaires et corrections

Type : CommentIn

Auteurs

Olivia Prior (O)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Carlos Macarro (C)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Víctor Navarro (V)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Camilo Monreal (C)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Marta Ligero (M)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Alonso Garcia-Ruiz (A)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Garazi Serna (G)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Sara Simonetti (S)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Irene Braña (I)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Maria Vieito (M)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Manuel Escobar (M)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Jaume Capdevila (J)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Annette T Byrne (AT)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Rodrigo Dienstmann (R)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Rodrigo Toledo (R)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Paolo Nuciforo (P)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Elena Garralda (E)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Francesco Grussu (F)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Kinga Bernatowicz (K)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Raquel Perez-Lopez (R)

From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Classifications MeSH